Affiliation:
1. Department of Medicine, New England Deaconess Hospital, Boston, Massachusetts 02215.
Abstract
In vitro activity of ramoplanin, a cyclic lipoglycopeptide, against 92 vancomycin-resistant gram-positive organisms was evaluated. Ramoplanin demonstrated potent activity against many highly vancomycin-resistant organisms including enterococci (MICs for 90% of strains tested of 0.5 micrograms/ml) and against Lactobacillus spp., Leuconostoc spp., and Pediococcus spp., all of which were inhibited at concentrations of < or = 0.25 micrograms/ml. This drug or a derivative compound merits further investigation as a potential therapeutic agent for infections due to vancomycin-resistant enterococci.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference14 articles.
1. In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms;Collins L. A.;Antimicrob. Agents Chemother.,1993
2. In vitro activity of ramoplanin against vancomycin-resistant gram-positive organisms;Collins L.;Abstr.,1992
3. Resistance of enterococci to glycopeptides;Courvalin P.;Antimicrob. Agents Chemother.,1990
4. Eliopoulos G. M. 1992. Enterococcal endocarditis p. 209-223. In D. Kaye (ed.) Infective endocarditis 2nd ed. Raven Press Ltd. New York.
5. In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria;Eliopoulos G. M.;Antimicrob. Agents Chemother.,1993
Cited by
47 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献